Literature DB >> 11092253

Liver-infiltrating CD56 positive T lymphocytes in hepatitis C virus infection.

K Yonekura1, T Ichida, K Sato, S Yamagiwa, M Uchida, S Sugahara, S Ito, T Abo, H Asakura.   

Abstract

AIM: Hepatitis C virus (HCV) is a major cause of post-transfusional and sporadic hepatitis, and leads to chronic liver disease. It has been suggested that virus-specific cytotoxic T lymphocytes are responsible for liver injuries that occur in HCV-infected patients. However, the detailed characteristics of these lymphocytes have not yet been defined. We have previously reported that CD56+ T lymphocytes, as intermediates between natural killer cell and T lymphocytes, predominantly infiltrated the liver and were increased in patients with chronic hepatitis related to HCV (CH-C).
MATERIAL AND METHODS: We obtained peripheral blood and liver tissues from 32 patients diagnosed as having CH-C, and 10 other liver disease patients (5 chronic hepatitis related to HBV, 5 alcoholics), and analyzed peripheral blood and liver-infiltrating lymphocytes using flow cytometric and immunohistochemical techniques.
RESULTS: The CD56+ T lymphocyte ratio in the liver of patients with a high histology activity index (HAI) score for chronic hepatitis was higher than that of patients with a low HAI score and patients with other liver diseases. In addition, T lymphocytes from patients with chronic hepatitis with a high HAI score carried mostly gamma delta-TCR. There was a correlation between the ratio of CH-C and serum alanine aminotransferase, category I (periportal inflammation and necrosis), and IV (fibrosis) of the HAI scoring system. The ratio was highest in zone 1 of the hepatic lobules.
CONCLUSION: The correlation between CD56+ T lymphocyte ratios and hepatocellular damage was examined. These findings suggest strongly that liver-infiltrating CD56+ T lymphocytes play an important pathologic role in hepatocellular injury in CH-C.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11092253     DOI: 10.1034/j.1600-0676.2000.020005357.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  7 in total

1.  Simultaneous evaluation of lymphocyte subpopulations in the liver and in peripheral blood mononuclear cells of HCV-infected patients: relationship with histological lesions.

Authors:  M Pernollet; E Jouvin-Marche; V Leroy; I Vigan; J-P Zarski; P N Marche
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

2.  CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection.

Authors:  A W Lin; S A Gonzalez; S Cunningham-Rundles; G Dorante; S Marshall; A Tignor; C Ha; I M Jacobson; A H Talal
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

3.  Natural killer cells suppress full cycle HCV infection of human hepatocytes.

Authors:  S-H Wang; C-X Huang; L Ye; X Wang; L Song; Y-J Wang; H Liang; X-Y Huang; W-Z Ho
Journal:  J Viral Hepat       Date:  2008-07-10       Impact factor: 3.728

4.  T helper, cytotoxic T lymphocyte, NK cell and NK-T cell subpopulations in patients with chronic hepatitis C.

Authors:  R Amaraa; H Marecková; P Urbánek; T Fuciková
Journal:  Folia Microbiol (Praha)       Date:  2002       Impact factor: 2.099

Review 5.  Functionally Diverse NK-Like T Cells Are Effectors and Predictors of Successful Aging.

Authors:  Joshua J Michel; Patricia Griffin; Abbe N Vallejo
Journal:  Front Immunol       Date:  2016-11-24       Impact factor: 7.561

6.  Activation of Vgamma9Vdelta2 T cells by non-peptidic antigens induces the inhibition of subgenomic HCV replication.

Authors:  Chiara Agrati; Tonino Alonzi; Rafaella De Santis; Concetta Castilletti; Isabella Abbate; Maria Rosaria Capobianchi; Gianpiero D'Offizi; Francesca Siepi; Gian Maria Fimia; Marco Tripodi; Fabrizio Poccia
Journal:  Int Immunol       Date:  2005-12-16       Impact factor: 4.823

Review 7.  Antiviral reactivities of gammadelta T cells.

Authors:  Fabrizio Poccia; Chiara Agrati; Federico Martini; Maria Rosaria Capobianchi; Marianne Wallace; Miroslav Malkovsky
Journal:  Microbes Infect       Date:  2005-03-03       Impact factor: 2.700

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.